Pharmaceutical Market Europe • March 2025 • 3

COMMENT

Breaking down the barriers

In our cover story this month, Danny Buckland looks at breaking down the barriers in order to liberate omnichannel’s full potential, and why it’s so important to personalise the message to avoid HCPs wanting to unsubscribe.

As Danny says: “Connecting with precision and efficiency is now critical, as almost 70% of HCPs are digital natives with high levels of tech dependency and expectation, while 57% of HCPs prefer omnichannel engagement with pharma.”

“Digital advances offer an opportunity to provide HCPs with the content of their choice, but too often the experience has been off-key because of omnichannel confusion and overload. However, orchestrating omnichannel engagement is creating amplified impact across a range of touchpoints, thanks to intelligence-driven data management and system design that is enhancing customer experience. Find out more on page 28.

Also in this issue, the article on rare diseases by Chris Moore looks at how companies can help to speed up patient access to life-changing treatments by sharing how they’re adapting their launch strategies and engaging more deeply with physicians and experts.  As Chris says: “By 2030, the goal is to support the development of 1,000 new therapies in Europe. Currently, less than 5% of rare diseases have at least one EU-approved treatment and it can take up to five years for adults to receive a diagnosis.” Turn to page 16 for more.

The article on ALS on page 24 highlights revolutionary technological developments in ALS care through technological advancements and investigational treatments. As Romina Dibra says: “Although scientists are yet to develop a cure, recent technological advancements have made significant progress in the management of this complex disease. These innovations not only aim to enhance early diagnosis but also significantly improve quality of life and provide more effective, personalised treatments.”

Our next issue, in April 2025, will look at enhancing patient engagement though shared decision-making. If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com

I hope you enjoy this issue!

Image

Iona Everson
Group Managing Editor

Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at  www.pmlive.com/register

Image

THE TEAM
Editorial:
Group Managing Editor
Iona Everson

Deputy Editor
Emily Kimber


Studio:
Executive Director
Karl Equi

Sales:
Business Director
Tara Lovegrove

EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation

Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim

Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences

Stefan Janssens
President EMEA, Cegedim Dendrite

John Morris
Partner, KPMG

Paul Pay
Chief business development officer, Norgine

Mark Rothera
Chief executive officer, Orchard Therapeutics

Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals

PUBLISHED BY
PMGroup Worldwide Ltd
44 Maiden Lane
Covent Garden
London
WC2E 7LN


CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com

Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.

© 2025 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.

The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW

Image
0